B of A Securities analyst Chase Mulvehill maintains Shell Midstream Partners (NYSE:SHLX) with a Underperform and raises the price target from $12.5 to $13.
Cybin Begins Study Using Kernel Flow Headsets To Measure Ketamine’s Effects On The Brain
The first study visit to measure the psychedelic effects of ketamine in the cerebral cortex blood flow is underway, announced Cybin…